We harness the potential of technology to advance scientific research and accelerate the development and delivery of medicines and vaccines to positively impact the health of people at scale.
Our Tech team and GSK partners play a key role in every aspect of our business – collaborating with various departments ranging from early scientific exploration to the manufacture and delivery of our medicines and vaccines. Through the strategic– use of automation and scalability processes and tasks, allowing our talented individuals to focus on what they do best – solving complex problems using creativity, human judgement, and deep expertise.
Our operations are built to facilitate hosting, network, and connectivity. By prioritising these essential elements, we empower our people to do their best work. Our processes are driven by effective collaboration, enabled by workspace tools and devices that help our employees work in an agile way.
We recognise that technology plays a pivotal role in enhancing business productivity and performance through constant improvements informed by learnings from analytics-ready digital data.
The Cyber security office protects our technology systems, infrastructure, and data from cyber-risks. We provide comprehensive security consulting services to GSK Tech, our business units, subsidiaries, and partner companies. Through a holistic approach to information security and risk management, we ensure the protection, safeguarding, and enhance business growth across our enterprise digital infrastructure.
We are committed to revolutionising our supply chain at every level by using data, AI, ML, robotics, and automation. This approach minimises disruptions, drives efficiency, improves product quality, and expands our capacity, ensuring a steady supply of our medicines and vaccines to meet patient needs at pace and scale.
We understand the power of data and technology in supporting the entire patient journey. From the moment our vaccines and medicines are prescribed, we leverage data and tech to ensure effective management of health conditions before, during, and after treatment.
This revolutionary approach to healthcare is transforming the way we engage with governments and policymakers. Together, we co-create pathways that unlock the responsible use of data and tech in the discovery, development and access of medicines and vaccines. By harnessing these advancements, we’re able to conquer diseases together in ways urgently needed and not before possible.
To drive innovation in our pipeline, we use the power of genetic data, genomic insights, patient insights, artificial intelligence (AI), and machine learning (ML). These cutting-edge technologies allow us to unravel biological mysteries and gain a deeper understand of the causes of disease. With technology, we can more effectively select and prioritise genetic targets, design the best medicines and vaccines to target specific areas and intervene in the role of these targets in disease. Additionally, we can identify the patients most likely to benefit from our treatments with greater precision, at the right point in their disease progression.
We are digitising our clinical trials, from early trial design through to patient recruitment, sample collection and regulatory submissions. Not only does this approach reduce costs, but it also accelerates the delivery of life-changing medicines to the patients who need them.
